These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19602536)

  • 1. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients.
    Hilbrands R; Huurman VA; Gillard P; Velthuis JH; De Waele M; Mathieu C; Kaufman L; Pipeleers-Marichal M; Ling Z; Movahedi B; Jacobs-Tulleneers-Thevissen D; Monbaliu D; Ysebaert D; Gorus FK; Roep BO; Pipeleers DG; Keymeulen B
    Diabetes; 2009 Oct; 58(10):2267-76. PubMed ID: 19602536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation.
    Roelen DL; Huurman VA; Hilbrands R; Gillard P; Duinkerken G; van der Meer-Prins PW; Versteeg-van der Voort Maarschalk MF; Mathieu C; Keymeulen B; Pipeleers DG; Roep BO; Claas FH
    Clin Exp Immunol; 2009 Apr; 156(1):141-8. PubMed ID: 19161445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression.
    Lee D; Keymeulen B; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Gillard P
    Transplantation; 2017 Sep; 101(9):2218-2227. PubMed ID: 27779572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of diabetes-associated autoantibodies after sequential intraportal islet allograft associated with kidney transplantation in type 1 diabetes.
    Vantyghem MC; Fajardy I; Pigny P; Noel C; Kerr-Conte J; Gmyr V; Vandewalle B; Proye C; Pattou F
    Diabetes Metab; 2003 Dec; 29(6):595-601. PubMed ID: 14707888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Culture to Reach Metabolically Adequate Beta-cell Dose by Combining Donor Islet Cell Isolates for Transplantation in Type 1 Diabetes Patients.
    Lee D; Gillard P; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Keymeulen B
    Transplantation; 2020 Oct; 104(10):e295-e302. PubMed ID: 32433237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients.
    van Kampen CA; van de Linde P; Duinkerken G; van Schip JJ; Roelen DL; Keymeulen B; Pipeleers DG; Claas FH; Roep BO
    Transplantation; 2005 Jul; 80(1):118-26. PubMed ID: 16003242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft.
    Keymeulen B; Gillard P; Mathieu C; Movahedi B; Maleux G; Delvaux G; Ysebaert D; Roep B; Vandemeulebroucke E; Marichal M; In 't Veld P; Bogdani M; Hendrieckx C; Gorus F; Ling Z; van Rood J; Pipeleers D
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17444-9. PubMed ID: 17090674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of neurotoxicity and beta-cell toxicity in an islet transplant recipient following substitution of tacrolimus with MMF.
    Froud T; Baidal DA; Ponte G; Ferreira JV; Ricordi C; Alejandro R
    Cell Transplant; 2006; 15(7):613-20. PubMed ID: 17176613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes.
    Bellin MD; Kandaswamy R; Parkey J; Zhang HJ; Liu B; Ihm SH; Ansite JD; Witson J; Bansal-Pakala P; Balamurugan AN; Papas KK; Sutherland DE; Moran A; Hering BJ
    Am J Transplant; 2008 Nov; 8(11):2463-70. PubMed ID: 18808408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid failure of pig islet transplantation in non human primates.
    Cantarovich D; Blancho G; Potiron N; Jugeau N; Fiche M; Chagneau C; Letessier E; Boeffard F; Loth P; Karam G; Soulillou JP; Le Mauff B
    Xenotransplantation; 2002 Jan; 9(1):25-35. PubMed ID: 12005101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary graft function, metabolic control, and graft survival after islet transplantation.
    Vantyghem MC; Kerr-Conte J; Arnalsteen L; Sergent G; Defrance F; Gmyr V; Declerck N; Raverdy V; Vandewalle B; Pigny P; Noel C; Pattou F
    Diabetes Care; 2009 Aug; 32(8):1473-8. PubMed ID: 19638525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.
    Shapiro AM; Lakey JR; Ryan EA; Korbutt GS; Toth E; Warnock GL; Kneteman NM; Rajotte RV
    N Engl J Med; 2000 Jul; 343(4):230-8. PubMed ID: 10911004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of glucocorticoid-free immunosuppressive regimen in allogenic islet transplantation.
    Du CY; Xu EK
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):43-7. PubMed ID: 16481281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy.
    Gillard P; Rustandi M; Efendi A; Lee DH; Ling Z; Hilbrands R; Kuypers D; Mathieu C; Jacobs-Tulleneers-Thevissen D; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2014 Aug; 98(4):451-7. PubMed ID: 24770614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreata from pediatric donors restore insulin independence in adult insulin-dependent diabetes mellitus recipients.
    Socci C; Orsenigo E; Santagostino I; Caumo A; Caldara R; Parolini D; Aldrighetti L; Castoldi R; Frasson M; Carvello M; Ghirardelli L; Secchi A; Di Carlo V; Staudacher C
    Transplant Proc; 2010; 42(6):2068-70. PubMed ID: 20692410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation.
    Kuypers DR; Malaise J; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii33-9, ii62. PubMed ID: 15814548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.
    Huurman VA; Hilbrands R; Pinkse GG; Gillard P; Duinkerken G; van de Linde P; van der Meer-Prins PM; Versteeg-van der Voort Maarschalk MF; Verbeeck K; Alizadeh BZ; Mathieu C; Gorus FK; Roelen DL; Claas FH; Keymeulen B; Pipeleers DG; Roep BO
    PLoS One; 2008 Jun; 3(6):e2435. PubMed ID: 18560516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ET-Kyoto ductal injection and density-adjusted purification combined with potent anti-inflammatory strategy facilitated single-donor islet transplantation: case reports.
    Matsumoto S; Noguchi H; Takita M; Shimoda M; Tamura Y; Olsen G; Naziruddin B; Onaca N; Levy MF
    Transplant Proc; 2010; 42(6):2159-61. PubMed ID: 20692433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients.
    Gillard P; Hilbrands R; Van de Velde U; Ling Z; Lee DH; Weets I; Gorus F; De Block C; Kaufman L; Mathieu C; Pipeleers D; Keymeulen B
    Diabetes Care; 2013 Nov; 36(11):3483-8. PubMed ID: 24041683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.